



SANDU PHARMACEUTICALS LTD

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.
Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in

Ref: SPL/CORP-SEC/2020-21/BSE/1283

Dated: 13.11.2020

To,

Bombay Stock Exchange Ltd,
Phirojshah Jeejobhoy Towers,
25th Floor, Dalal Street,
Mumbai 400 001

Manager-Department of Corporate affairs

Sir,

Sub: Outcome of the Board Meeting for the FY 2020-21 held on Friday, 13th November 2020 with Scrip Code 524703.

A Meeting of the Board of Directors of the Company duly convened on Friday, 13th November 2020 at 4:30 p.m. and Concluded at 5.40 p.m. at the Corporate Office of the Company at Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai 400071 inter alia, discussed the following business:-

- (a) It has approved Unaudited Financial Results for the Quarter ended 30th September 2020 along with Limited Review Report.

You are requested to kindly take the same on record.

Yours Faithfully,

For Sandu Pharmaceuticals Limited



Company Secretary



AN ISO 9001:2008 CERTIFIED ORGANISATION

Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.
Tel.: +91 22 2528 4402 / 3306, Fax: +91 22 2528 2403, E-mail: info@sandu.in, Web: www.sandu.in

CIN:L24233GA1985PLC001587




Sandu Pharmaceuticals Ltd

STATEMENT OF UNAUDITED RESULTS FOR THE PERIOD ENDED 30/09/20

Particulars	Quarter ended			Half Year ended		Previous Year Ended 31 March 2020 Audited
	Quarter Ended 30-09- 2020	Corresponding Quarter Ending June 2020	Corresponding Quarter year ended 30-09-2019	Half Year ended 30-09- 2020	Corresponding Half year ended 30-09-2019	
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	
I Revenue From Operations	1,722.15	1,166.97	1,182.51	2,889.12	2,417.04	4,836.74
II Other Income	6.69	2.38	13.54	9.07	27.96	45.27
III Total Income (I+II)	1,728.84	1,169.35	1,196.05	2,898.19	2,445.00	4,882.01
IV EXPENSES						
Cost of materials consumed	304.65	192.01	207.41	496.65	387.04	913.86
Purchases of Stock-in-Trade	534.47	211.83	252.21	746.29	616.20	1,700.87
Changes in inventories of finished Stock-in -Trade and work-in-	330.00	369.06	112.47	699.06	285.74	(103.38)
Excise duty on sale of goods						
Employee benefits expense	189.65	148.40	181.89	338.04	329.16	685.15
Finance costs	(2.82)	7.15	11.67	4.33	25.40	43.48
Depreciation and amortization	14.02	13.74	13.86	27.76	27.46	55.21
Other expenses	304.28	221.21	381.00	525.49	711.60	1,494.71
Total expenses (IV)	1,674.25	1,163.39	1,160.51	2,837.63	2,382.59	4,789.89
V Profit/(loss) before exceptional tax (I- IV)	54.59	5.96	35.54	60.56	62.41	92.12
VI Exceptional Items	-		0.44		0.44	0.22
VII Profit/(loss) before tax (V-VI)	54.60	5.96	35.10	60.56	61.97	91.90
VIII Tax expense:						
(1) Current tax	14.65	2.00	9.12	16.65	16.11	12.68
(2) Deferred tax	0.29	0.16	2.72	0.45	6.42	7.18
(3) Short /Excess Proviison					(14.80)	
IX Profit (Loss) for the period from continuing operations (VII-VIII)	39.66	3.80	23.26	43.46	54.24	72.04
X Profit/(loss) for the period (IX+XII)	39.66	3.80	23.26	43.46	54.24	72.04
XI Other Comprehensive Income						
A (i) Items that will not be profit or loss	7.87	14.68	(4.24)	22.55	1.91	(31.10)
(ii) Income tax relating to items not be reclassified to profit or loss	(0.82)	(1.52)	0.92	(2.34)	0.30	3.84
B (i) Items that will be reclassified profit or loss						
(ii) Income tax relating to items be reclassified to profit or loss						
Total Comprehensive Income for period (XIII+XIV)(Comprising (Loss) and Other Comprehensive	46.71	16.96	19.94	63.67	56.44	44.78
XIII Reserves Excluding Revaluation						
XIV Paid Up Equity Capital (Face Value of Rs 10/- Per share)	708.10	708.10	708.10	708.10	708.10	708.10
XVI Earnings per equity share (for operation):						
(1) Basic	0.56	0.05	0.33	0.61	0.77	1.02
(2) Diluted						

For Sandu Pharmaceuticals Ltd


Umesh Sandu
Managing Director
DIN :- 01132141



Mumbai

Date :-13.11.2020


Sandu Pharmaceuticals Ltd

STATEMENT OF ASSETS & LIABILITIES FOR THE HALF YEAR ENDED 30TH SEPTEMBER, 2020

Sr no	Particulars	As at 30 th September	As at 30 th March
		2020	2020
I	ASSETS		
	Non Current Assets		
	Property, plant & Equipment	1,629.01	1650.17
	Other Intangible Assets	10.16	10.15
	Financial Assets		
	Investments	104.91	82.36
	Loan Receivable	-	131.87
	Other Financial Asset	0.15	0.15
	Other current assets	-	24.60
	Current Assets	1,744.23	1899.30
	Inventories	777.30	1436.17
	Financial Asset		
	Investments	-	-
	Trade Receivables	779.16	468.11
	Cash & Cash Equivalents	465.95	121.66
	Bank & other Cash Equivalents	297.24	32.50
	c) Other Current Assets	205.90	183.42
	Total of Curent Assets	2,525.55	2241.86
	TOTAL ASSETS	4,269.81	4141.16
	EQUITY & LIABILITIES		
	a) Equity Share Capital	708.10	708.10
	b) Other Equity	2,279.23	2215.56
	Total Equity	2,987.33	2923.66
II	LIABILITIES		
	Non -Current Liabilities		
	a) Financial liabilities		
	i) Borrowings	-	-
	ii) Other Financial Liabilities		
	b) Deferred Tax	87.31	84.51
	Total Non current Liabilities	87.31	84.51
	Current Liability		
	a) Financial liabilities		
	Borrowings	349.21	124.50
	Trade Payables		
	Dues to Micro & Small Enterprises	1.76	3.18
	Other than Micro & Small Enterprises	337.82	572.69
	iii) other financial Liabilities		
	b) Other Current Liabilities	124.19	114.618
	c) Provisions	382.16	318.01
	Total current Liabilities	1,195.14	1132.99
	Total Liabilites	4,269.81	4141.16

For Sandu Pharmaceuticals Ltd

Umesh Sandu
Managing Director
DIN :- 01132141



Place :- Mumbai

Date :- 13 th November, 2020

SANDU PHARMACEUTICALS LIMITED


Statement of Cash Flow for the year ended 30th Sept, 2020

Particulars	Year ended 30th Sept, 2020		Year ended 31st March, 2020	
	Amount (₹)	Amount (₹)	Amount (₹)	Amount (₹)
A. Cash flow from operating activities				
Net Profit / (Loss) before extraordinary items and tax		6,056,676		9,190,308
Adjustments for:				
Depreciation and amortisation expenses	2,775,703		5,521,731	
Finance costs	432,702		4,348,151	
Interest income	299,124		(171,967)	
Dividend income	(13,209)		(45,235)	
Profit on sale of Property, Plant and Equipment			(75,873)	
		3,494,321		9,576,807
Operating profit / (loss) before changes in operating assets & liabilities		9,550,996		18,767,115
Changes in operating assets				
(increase) / decrease in inventories	65,886,991		(11,062,319)	
(increase) / decrease in Trade receivables	(31,105,240)		1,142,962	
(increase) / decrease in other operating assets	14,286,250		35,138,252	
Changes in operating liabilities				
(increase) / decrease in trade payables	(23,628,509)		15,251,186	
(increase) / decrease in other operating liabilities	5,707,572	31,147,064	4,198,287	44,668,368
Cash Generated from operation		40,698,060		63,435,483
Income Tax Paid		(886,294)		(1,413,914)
Net Cash flow from Operating activities		39,811,766		62,021,569
B. Cash flow from investing activities				
Purchases of Property, Plant and Equipment	(660,431)		(1,123,242)	
Purchases of Fixed Deposits	(29,724,475)			
Proceeds from sale of fixed assets				
Interest received	(299,124)		171,967	
Dividend received	13,209		45,235	
Gain on Sale of Financial Instruments	-		-	
Net cash flow from / (used in) investing activities (B)		(30,670,822)		(906,040)
C. Cash flow from financing activities				
Proceeds from long-term borrowings	-			
Repayment of long-term borrowings			(2,442,803)	
Repayment of Short-term borrowings	22,471,215		(46,804,245)	
Finance cost	(432,702)		(4,348,151)	
Net cash flow from / (used in) financing activities (C)		22,038,512		(53,595,199)
Net increase / (decrease) in Cash and cash equivalents (A+B+C)		31,179,457		7,520,330
Cash and cash equivalents at the beginning of the year		15,416,122		7,895,797
Cash and cash equivalents at the end of the year		46,595,578		15,416,122

Dated : 13/11/2020
Place: Mumbai

For Sandu Pharmaceuticals Ltd

Umesh Sandu
Managing Director
DIN :- 01132141




1. The above results published in accordance with regulation 33 of the SEBI (Listing Obligation & Disclosures Requirements), 2015 have been reviewed by the Audit committee and approved by the Board of Directors at their meeting held on 13th November, 2020. The Financials results are in accordance with the Indian Accounting Standards (IND AS) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rule, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2017.
2. The Management evaluates the performance of the company based on revenue and operating income in one segment i.e. "Ayurvedic Property Medicines". Accordingly, as per IND AS- 108. The company has only one business segment and hence segment information has not been separately disclosed.
3. The Company has considered the possible impact of COVID-19 pandemic on its operations, liquidity position and recoverability of its asset balances at 30th September, 2020 based on the internal and external information up to the date of approval of these financial results. The impact of COVID-19 may be different from that estimated as at the date of approval of these financial results and management will continue to monitor any material changes arising due to the impact of this pandemic on financial and operational performance of the Company and take necessary measures to address the situation.
4. The Figures for the quarter ended 31st March, 2020 are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the respective financial year.
5. Figures for the previous periods have been reclassified/regrouped, whenever necessary.
6. The Above results are reviewed and recommended by the audit committee and approved by Board of Directors at the meeting held on 13th November, 2020 and there are no qualification in the audit report for the quarter ended, 30th September, 2020.

Date: - 13/11/2020

For Sandu Pharmaceuticals Ltd


Umesh Sandu
Managing Director
DIN :- 01132141





**"LIMITED REVIEW" REPORT ON THE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER
AND HALF YEAR ENDED ON 30TH SEPTEMBER, 2020**


To,

**The Board of Directors,
Sandu Pharmaceuticals Limited,
Plot No. 25, 26, 29 & 30,
Pilerne Industrial Estate, Marra,
Bardez, Goa-403511.**

Dear Sirs,

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **Sandu Pharmaceuticals Limited** ("the Company") for the quarter and half year ended on 30th Sep, 2020, prepared by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind As 34), prescribed under section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these standalone financial statements based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Unaudited Financial Results prepared in accordance with the applicable Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognised accounting practices and principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Dileep & Prithvi
Chartered Accountants
Firm Registration Number: 122290W


Himmat Mali
(Partner)

Membership Number: 183378
UDIN- 20183378AAAABI8334



Place: Mumbai
Date: 13th November, 2020